diazoxide has been researched along with Neutropenia in 4 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism." | 9.30 | Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism. ( Hamby, T; Nedrelow, J; Reynolds, C; Thornton, P; Truong, L, 2019) |
| " The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide." | 7.88 | Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. ( Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018) |
| "The cause of the hyperinsulinemia proved to be classical Munchausen by proxy." | 5.36 | Anemia and neutropenic fever with high dose diazoxide treatment in a case with hyperinsulinism due to Munchausen by proxy. ( Demirbilek, H; Ertugrul, A; Gumruk, F; Kandemir, N; Ozon, A; Unal, S, 2010) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 5.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| "Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism." | 5.30 | Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism. ( Hamby, T; Nedrelow, J; Reynolds, C; Thornton, P; Truong, L, 2019) |
| " The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide." | 3.88 | Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. ( Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018) |
| "The cause of the hyperinsulinemia proved to be classical Munchausen by proxy." | 1.36 | Anemia and neutropenic fever with high dose diazoxide treatment in a case with hyperinsulinism due to Munchausen by proxy. ( Demirbilek, H; Ertugrul, A; Gumruk, F; Kandemir, N; Ozon, A; Unal, S, 2010) |
| "Diazoxide treatment remains the mainstay of medical therapy." | 1.35 | Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. ( Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herrera, A | 1 |
| Vajravelu, ME | 1 |
| Givler, S | 1 |
| Mitteer, L | 1 |
| Avitabile, CM | 1 |
| Lord, K | 1 |
| De León, DD | 1 |
| Thornton, P | 1 |
| Truong, L | 1 |
| Reynolds, C | 1 |
| Hamby, T | 1 |
| Nedrelow, J | 1 |
| Yildizdas, D | 1 |
| Erdem, S | 1 |
| Küçükosmanoglu, O | 1 |
| Yilmaz, M | 1 |
| Yüksel, B | 1 |
| Ozon, A | 1 |
| Demirbilek, H | 1 |
| Ertugrul, A | 1 |
| Unal, S | 1 |
| Gumruk, F | 1 |
| Kandemir, N | 1 |
1 trial available for diazoxide and Neutropenia
| Article | Year |
|---|---|
Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism.
Topics: Diazoxide; Female; Humans; Hyperinsulinism; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; | 2019 |
3 other studies available for diazoxide and Neutropenia
| Article | Year |
|---|---|
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Topics: Congenital Hyperinsulinism; Diazoxide; Dose-Response Relationship, Drug; Drug Administration Schedul | 2018 |
Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Topics: Congenital Hyperinsulinism; Diazoxide; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infan | 2008 |
Anemia and neutropenic fever with high dose diazoxide treatment in a case with hyperinsulinism due to Munchausen by proxy.
Topics: Anemia; Bone Marrow; Child; Diazoxide; Female; Fever; Humans; Hyperinsulinism; Munchausen Syndrome b | 2010 |